Larimar Therapeutics Inc(LRMR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.98 | Insider Own | 54.01% | Shs Outstand | 103.9M | Perf Week | 17.62% |
| Market Cap | 0.28B | Forward P/E | - | EPS next Y | 14.62% | Insider Trans | 0.09% | Shs Float | 48.0M | Perf Month | -16.43% |
| Enterprise Value | 0.13B | PEG | - | EPS next Q | -0.34 | Inst Own | 49.71% | Short Float | 30.55% | Perf Quarter | -30.1% |
| Income | -0.17B | P/S | - | EPS this Y | 39.62% | Inst Trans | 5.79% | Short Ratio | 11.14 | Perf Half Y | -34.24% |
| Sales | 0.00B | P/B | 2.19 | EPS next 5Y | 38.33% | ROA | -109.49% | Short Interest | 14.66M | Perf YTD | -29.92% |
| Book/sh | 1.22 | P/C | 1.77 | EPS past 3/5Y | -18.15% 8.74% | ROE | -139.63% | 52W High | -58.41% ($6.42) | Perf Year | -38.05% |
| Cash/sh | 1.5 | P/FCF | - | Sales past 3/5Y | - | ROIC | -131.62% | 52W Low | 39.43% ($1.91) | Perf 3Y | 0.38% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -27% | Gross Margin | - | Volatility(W/M) | 8.51% 8.62% | Perf 5Y | -77.66% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.21 | Perf 10Y | -92.73% |
| Dividend Ex-Date | - | Quick Ratio | 4.7 | EPS Q/Q | 23.18% | Profit Margin | - | RSI (14) | 49.4 | Recom | 1.1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.7 | Sales Q/Q | - | SMA20 | 9.17% ($2.45) | Beta | 0.69 | Target Price | $14.89 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/4 | SMA50 | -17.79% ($3.25) | Rel Volume | 0.78 | Prev Close | $2.54 |
| Employees | 71 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 21.36% - | SMA200 | -29.97% ($3.81) | Avg Volume(3M) | 1.32M | Price | $2.67 |
| IPO | 2014/6/19 | Option/Short | Yes/Yes | Trades | 3693 | Volume | 1,027,353 | Change | 5.12% |
🧬 Larimar Therapeutics (ticker LRMR) is a US clinical-stage biotech company focused on developing treatments for rare genetic diseases. Through its lead candidate, nomlabofusp, the company pursues a protein replacement approach that supplements frataxin protein deficiency—the root cause of Friedreich's ataxia—building a differentiated pipeline in the rare disease space.
Over the past 1 year, on the lower side
58% below its 1-year high.
Traded less than usual. That is 78% of its average volume.
LRMR has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +39.6% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -77.7%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
30.6% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #272 of 594 in the industry
Based on market cap of $277M.
GLSI#270 Greenwich LifeSciences Inc $279M PER - 
RCKT#271 Rocket Pharmaceuticals Inc $279M PER - LRMR#272 Larimar Therapeutics Inc $277M PER - 
LYEL#273 Lyell Immunopharma Inc $277M PER - 
CABA#274 Cabaletta Bio Inc $269M PER - 
FAQ
What kind of company is LRMR?
LRMR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LRMR?
The market cap of LRMR is approximately $277M, ranking 3,745 within its sector.
What is the 52-week high and low for LRMR?
LRMR has recorded a 52-week high of $6.42 and a low of $1.91.
